November 10, 2014 - ZOLL Technology for Improving CPR Quality to be Showcased at American Heart Association Annual Conference



Diane Egan
ZOLL Medical Corporation
+1 (978) 421-9637
[email protected]



November 10, 2014—CHELMSFORD, MASS.—ZOLL® Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that its advanced resuscitation technology, which supports the American Heart Association’s emphasis on improving CPR quality to increase survival from sudden cardiac arrest, will be on display during the American Heart Association (AHA) 2014 Resuscitation Science Symposium (ReSS) and Scientific Sessions in Booth #300 November 17-19 in Chicago.

Improving CPR quality has been an ongoing commitment of ZOLL since 2002, when it was the first to introduce real-time CPR feedback in a defibrillator, its AED Plus®. Today, virtually all ZOLL defibrillators, from AEDs to professional manual defibrillators, feature Real CPR Help®, the only CPR-feedback technology that, in combination with training, has been shown to impact survival to discharge, as demonstrated in published research.1
ZOLL’s commitment to high-quality CPR is also evident in the company’s suite of tools for optimal resuscitation response, which includes See-Thru CPR® as well as EtCO2 monitoring. See-Thru CPR, ZOLL’s proprietary technology which minimizes the duration of pauses in CPR to enable rescuers to see an organized, underlying rhythm, is available on the R Series®, the X Series®, and the AED Pro®.
Highlights among ZOLL’s clinical portfolio in Booth #300 include:

  • The R Series Code-Ready® Monitor/Defibrillators are designed to extend “Simple, Smart, and Ready” defibrillation to every hospital department through advanced, cost-effective solutions for resuscitation.
  • The X Series Monitor/Defibrillator is ideal for transporting critically ill patients. It is lightweight with extensive monitoring capabilities.
  • OneStep™ Pediatric CPR Electrodes are the only electrodes on the market with a built-in CPR sensor that reports CPR quality on young children up to 8 years of age. This first-of-its-kind electrode provides optimal support for pediatric resuscitation when paired with the ZOLL R Series Monitor/Defibrillator and its CPR Dashboard™.
  • The AutoPulse® Non-Invasive Cardiac Support Pump is the only mechanical CPR system that has shown improved outcomes in comparative clinical trials. In a meta-analysis of 12 clinical trials, the AutoPulse improved the odds of return of spontaneous circulation (ROSC) by 62% compared to manual CPR.2 The CIRC trial, the largest prospective, randomized trial of mechanical chest compression ever completed, confirmed that the AutoPulse is equivalent to high-quality manual CPR, as measure by survival to hospital discharge.3  
  • The LifeVest® Wearable Defibrillator is worn by patients at risk for sudden cardiac arrest (SCA), providing protection during their changing condition and while permanent SCA risk has not been established. The LifeVest continuously monitors the patient’s heart and, if a life-threatening heart rhythm is detected, the device delivers a treatment shock to restore normal heart rhythm. The LifeVest is lightweight and easy to wear, and allows a patient’s physician time to assess his or her long-term arrhythmic risk and make appropriate plans.
  • ZOLL’s Intravascular Temperature Management (IVTM™) System offers health care providers the precision and control they need to rapidly, safely, and effectively manage the core body temperature of critically ill or surgical patients. The Thermogard XP® delivers accurate, easy-to-use and cost-effective control for both cooling and warming applications. This temperature management system provides a variety of catheter options depending upon the specific patient needs.

Scientific presentations related to ZOLL products and technology

Fifteen scientific presentations related to ZOLL products and technology are scheduled to be presented during ReSS. Key presentations held Central time are:

  • Chingping Wan, MD, will present “The Wearable Cardioverter Defibrillator Protects Older Patients from Sudden Cardiac Death,” Sunday, November 16 at 8:00-9:30 a.m. in the McCormick Place Lakeside Ballroom E354. Poster 341.
  • Uwe Stolz, PhD, will present “Time in CPR is Significantly Related to CPR Quality and Survival,” Sunday, November 16 at 8:00-9:30 a.m. in the McCormick Place Lakeside Ballroom E354. Poster 295.
  • Joshua W. Lampe, PhD, will present “Can We Personalize CPR? Challenges With Hemodynamics, Monitoring, and Pharmacology,” Tuesday, November 18 at 9:00 a.m.–5:00 p.m. in the McCormick Place South Hall A2-Core 4. Poster 16289.
  • Ramu Perumal, PhD, will present “Wearable Cardioverter Defibrillator Treatment Characteristics and Outcomes in Recent Myocardial Infarction Patients with Heart Failure,” Tuesday, November 18 at 3:00-4:30 p.m. in the McCormick Place South Hall A2-Core 4. Poster 16255.
  • Rajesh Dash, MD, will present “Moderate Hypothermia Reduces Infarct/Injury Size and Preserves Myocardial Function Following Acute Ischemia-Reperfusion Injury,” Tuesday, November 18 at 3:00-4:30 p.m. in the South Hall A2-Core 5. Poster 19073.

A listing and schedule of the ZOLL-related presentations is available at

About ZOLL Medical Corporation

ZOLL Medical Corporation, an Asahi Kasei Group company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and acute critical care. For more information, visit

About Asahi Kasei

The Asahi Kasei Group is a diversified group of companies led by holding company Asahi Kasei Corp., with operations in the chemicals and fibers, homes and construction materials, electronics, and health care business sectors. Its health care operations include devices and systems for acute critical care, dialysis, therapeutic apheresis, transfusion, and manufacture of biotherapeutics, as well as pharmaceuticals, diagnostic reagents, and nutritional products. With more than 29,000 employees around the world, the Asahi Kasei Group serves customers in more than 100 countries. For more information, visit

Copyright © 2014 ZOLL Medical Corporation. All rights reserved. AED Plus, AED Pro, AutoPulse, Code-Ready, CPR Dashboard, IVTM, LifeVest, OneStep, Real CPR Help, R Series, See-Thru CPR, X Series, Thermogard XP, and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries. Asahi Kasei is a registered trademark of Asahi Kasei Corporation. All product names are the property of their respective owners.

1Bobrow BJ, et al. The Influence of Scenario-based Training and Real-time Audiovisual Feedback on Pre-hospital Cardiopulmonary Resuscitation Quality and Survival from Out-of-hospital Cardiac Arrest. Ann Emerg Med. 2013 Jul;62(1):47–56.e1. Epub 2013 Mar 7.
2Wesfall M, et al. Mechanical Vs. Manual Chest Compressions in Out-of-Hospital Cardiac Arrest: A Meta-Analysis. Crit Care Med. 2013 Jul;41(7):1782‐9.
3Wik L, et al. Manual vs. Integrated Automatic Load-distributing Band CPR with Equal Survival after Out- of- Hospital Cardiac Arrest. The Randomized CIRC Trial. Resuscitation 85 (2014) 741–748.